<DOC>
	<DOCNO>NCT00023426</DOCNO>
	<brief_summary>Randomized , double-blind study tolerability three different dos rifapentine</brief_summary>
	<brief_title>TBTC Study 25 : Study Tolerability Higher Doses Rifapentine Treatment Tuberculosis</brief_title>
	<detailed_description>Prospective , randomize , double-blinded , comparative study . Patients randomized completion induction phase therapy . Sample-size 50 HIV-seronegative patient culture-positive , drug susceptible TB treatment arm . The first 75 patient randomize 2:1 900 mg:600 mg rifapentine . The second 75 patient randomize 2:1 1200 mg:600 mg rifapentine . The DSMB review tolerability safety data first 21 patient enrol ( 900 mg 600 mg dos ) approve proceed enrollment 1200 mg dose .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Inclusions : 1 . Drug susceptible culturepositive tuberculosis 2 . Adequate induction therapy 3 . Age &gt; 18 4 . Normal screen labs 5 . Karnofsky &gt; =60 6 . Informed consent 7 . Birth control child bear potential Exclusions : 1 . SilicoTB 2 . Skeletal CNS TB 3 . Pregnant breastfeed 4 . Intolerance INH rifamycins 5 . Over 70 day TB treatment prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>tb</keyword>
	<keyword>rifapentine</keyword>
	<keyword>safety</keyword>
	<keyword>dose</keyword>
</DOC>